Company intelligence / Profile preview

Microbion

Bozeman, Montana, United Statesmicrobioncorp.com ↗

Ownership: Private
Development stage: Phase 2

Overview

MBN‑101 has demonstrated broad-spectrum antibacterial efficacy in vitro against a wide range of pathogens—including CDC priority superbugs—and can prevent and eradicate microbial biofilms. This dual-action mechanism positions it as a potential first-in-class therapy for serious resistant infections. Clinical results to date support continued development but specific trial outcomes are not detailed in the provided sources.

Therapeutic areas: Infectious Diseases
Modalities: Small molecules (novel class of antimicrobial/anti-biofilm compounds)
Industry: Biotech

Drug pipeline

1 asset

pravibismane

Beyond the preview

Go deeper on Microbion.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Microbion.

Explore the full profile